Days after Takeda Pharmaceutical Co. Ltd. said it would continue to divest non-core assets to hone its strategic focus, the Japanese company has taken another step to that end by licensing out rights to a gastrointestinal drug in major western markets to a new US venture.
Phathom Pharmaceuticals has just been established to focus on the development and commercialization of novel treatments for gastrointestinal disorders, and will take on Takeda’s oral
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?